25 XP   0   0   10

DNA Biomed Solns
Buy, Hold or Sell?

Let's analyse DNA Biomed Solns together

PenkeI guess you are interested in DNA Biomed Solns. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of DNA Biomed Solns. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about DNA Biomed Solns

I send you an email if I find something interesting about DNA Biomed Solns.

Quick analysis of DNA Biomed Solns (30 sec.)










What can you expect buying and holding a share of DNA Biomed Solns? (30 sec.)

How much money do you get?

How much money do you get?
ILA0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
ILA64.29
Expected worth in 1 year
ILA61.31
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
ILA-2.98
Return On Investment
-3.4%

For what price can you sell your share?

Current Price per Share
ILA88.10
Expected price per share
ILA68.00 - ILA105.00
How sure are you?
50%

1. Valuation of DNA Biomed Solns (5 min.)




Live pricePrice per Share (EOD)

ILA88.10

Intrinsic Value Per Share

ILA-7.37 - ILA-0.25

Total Value Per Share

ILA56.92 - ILA64.04

2. Growth of DNA Biomed Solns (5 min.)




Is DNA Biomed Solns growing?

Current yearPrevious yearGrowGrow %
How rich?$21.3m$21.6m-$248k-1.2%

How much money is DNA Biomed Solns making?

Current yearPrevious yearGrowGrow %
Making money-$317.6k-$6.3m$6m1,899.7%
Net Profit Margin-384.6%-4,202.9%--

How much money comes from the company's main activities?

3. Financial Health of DNA Biomed Solns (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

What can you expect buying and holding a share of DNA Biomed Solns? (5 min.)

Welcome investor! DNA Biomed Solns's management wants to use your money to grow the business. In return you get a share of DNA Biomed Solns.

What can you expect buying and holding a share of DNA Biomed Solns?

First you should know what it really means to hold a share of DNA Biomed Solns. And how you can make/lose money.

Speculation

The Price per Share of DNA Biomed Solns is ILA88.10. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of DNA Biomed Solns.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in DNA Biomed Solns, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ILA64.29. Based on the TTM, the Book Value Change Per Share is ILA-0.75 per quarter. Based on the YOY, the Book Value Change Per Share is ILA20.93 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ILA0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of DNA Biomed Solns.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per Share
Usd Eps0.000.0%0.000.0%-0.05-0.1%-0.030.0%-0.010.0%
Usd Book Value Change Per Share0.000.0%0.000.0%0.060.1%0.010.0%0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%0.000.0%0.060.1%0.010.0%0.010.0%
Usd Price Per Share0.17-0.17-0.20-0.24-0.38-
Price to Earnings Ratio-66.13--66.13--3.84--13.28--13.67-
Price-to-Total Gains Ratio-84.70--84.70-3.51--16.77-2,540.16-
Price to Book Ratio0.98-0.98-1.13-4.05--2.59-
Price-to-Total Gains Ratio-84.70--84.70-3.51--16.77-2,540.16-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.2377819
Number of shares4205
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.01
Usd Total Gains Per Share0.000.01
Gains per Quarter (4205 shares)-8.4726.32
Gains per Year (4205 shares)-33.87105.30
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-34-44010595
20-68-780211200
30-102-1120316305
40-135-1460421410
50-169-1800526515
60-203-2140632620
70-237-2480737725
80-271-2820842830
90-305-3160948935
100-339-350010531040

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%2.08.00.020.0%2.09.07.011.1%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%2.03.00.040.0%4.06.00.040.0%8.010.00.044.4%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.018.00.0%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%2.03.00.040.0%4.06.00.040.0%8.010.00.044.4%

Fundamentals of DNA Biomed Solns

About DNA Biomed Solns

Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physicians, nurses, and operators in hospitals and clinics, as well as in pharmacies and other places. In addition, it engages in the development of oral drugs. The company was formerly known as D.N.A Biomedical Solutions Ltd. and changed its name to Dna Group (T.R.) Ltd in November 2022. Dna Group (T.R.) Ltd was incorporated in 2004 and is based in Tel Aviv-Yafo, Israel.

Fundamental data was last updated by Penke on 2024-04-21 04:53:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of DNA Biomed Solns.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit DNA Biomed Solns earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare DNA Biomed Solns to the Biotechnology industry mean.
  • A Net Profit Margin of -384.6% means that -3.85 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of DNA Biomed Solns:

  • The MRQ is -384.6%. The company is making a huge loss. -2
  • The TTM is -384.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-384.6%TTM-384.6%0.0%
TTM-384.6%YOY-4,202.9%+3,818.2%
TTM-384.6%5Y-917.5%+532.9%
5Y-917.5%10Y-458.7%-458.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-384.6%-207.2%-177.4%
TTM-384.6%-214.6%-170.0%
YOY-4,202.9%-281.4%-3,921.5%
5Y-917.5%-428.1%-489.4%
10Y-458.7%-595.4%+136.7%
1.1.2. Return on Assets

Shows how efficient DNA Biomed Solns is using its assets to generate profit.

  • Above 5% is considered healthy but always compare DNA Biomed Solns to the Biotechnology industry mean.
  • -1.5% Return on Assets means that DNA Biomed Solns generated -0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of DNA Biomed Solns:

  • The MRQ is -1.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.5%TTM-1.5%0.0%
TTM-1.5%YOY-28.7%+27.2%
TTM-1.5%5Y-41.1%+39.7%
5Y-41.1%10Y-48.7%+7.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.5%-12.9%+11.4%
TTM-1.5%-12.3%+10.8%
YOY-28.7%-11.2%-17.5%
5Y-41.1%-13.5%-27.6%
10Y-48.7%-15.1%-33.6%
1.1.3. Return on Equity

Shows how efficient DNA Biomed Solns is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare DNA Biomed Solns to the Biotechnology industry mean.
  • -1.5% Return on Equity means DNA Biomed Solns generated -0.01 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of DNA Biomed Solns:

  • The MRQ is -1.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.5%TTM-1.5%0.0%
TTM-1.5%YOY-29.4%+27.9%
TTM-1.5%5Y-75.2%+73.7%
5Y-75.2%10Y-18.5%-56.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.5%-16.5%+15.0%
TTM-1.5%-15.7%+14.2%
YOY-29.4%-14.1%-15.3%
5Y-75.2%-18.8%-56.4%
10Y-18.5%-19.7%+1.2%

1.2. Operating Efficiency of DNA Biomed Solns.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient DNA Biomed Solns is operating .

  • Measures how much profit DNA Biomed Solns makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare DNA Biomed Solns to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated 0.00  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of DNA Biomed Solns:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-1,017.7%+1,017.7%
TTM-5Y-203.5%+203.5%
5Y-203.5%10Y-101.8%-101.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--287.3%+287.3%
TTM--226.2%+226.2%
YOY-1,017.7%-287.8%-729.9%
5Y-203.5%-459.1%+255.6%
10Y-101.8%-598.1%+496.3%
1.2.2. Operating Ratio

Measures how efficient DNA Biomed Solns is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 8.10 means that the operating costs are 8.10 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of DNA Biomed Solns:

  • The MRQ is 8.105. The company is inefficient in keeping operating costs low. -1
  • The TTM is 8.105. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ8.105TTM8.1050.000
TTM8.105YOY11.177-3.072
TTM8.1055Y3.856+4.248
5Y3.85610Y1.928+1.928
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.1053.246+4.859
TTM8.1053.303+4.802
YOY11.1773.753+7.424
5Y3.8565.557-1.701
10Y1.9287.396-5.468

1.3. Liquidity of DNA Biomed Solns.

1.3. Liquidity
1.3.1. Current Ratio

Measures if DNA Biomed Solns is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 97.73 means the company has 97.73 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of DNA Biomed Solns:

  • The MRQ is 97.726. The company is very able to pay all its short-term debts. +2
  • The TTM is 97.726. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ97.726TTM97.7260.000
TTM97.726YOY83.563+14.163
TTM97.7265Y52.999+44.727
5Y52.99910Y26.904+26.095
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ97.7263.821+93.905
TTM97.7264.161+93.565
YOY83.5635.313+78.250
5Y52.9996.113+46.886
10Y26.9046.474+20.430
1.3.2. Quick Ratio

Measures if DNA Biomed Solns is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare DNA Biomed Solns to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off 0.00 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of DNA Biomed Solns:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.066-0.066
5Y0.06610Y0.061+0.004
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.474-3.474
TTM-3.993-3.993
YOY-5.388-5.388
5Y0.0666.105-6.039
10Y0.0616.442-6.381

1.4. Solvency of DNA Biomed Solns.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of DNA Biomed Solns assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare DNA Biomed Solns to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.02 means that DNA Biomed Solns assets are financed with 1.8% credit (debt) and the remaining percentage (100% - 1.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of DNA Biomed Solns:

  • The MRQ is 0.018. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.018. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.018TTM0.0180.000
TTM0.018YOY0.023-0.005
TTM0.0185Y0.170-0.152
5Y0.17010Y0.708-0.538
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0180.347-0.329
TTM0.0180.340-0.322
YOY0.0230.272-0.249
5Y0.1700.368-0.198
10Y0.7080.388+0.320
1.4.2. Debt to Equity Ratio

Measures if DNA Biomed Solns is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare DNA Biomed Solns to the Biotechnology industry mean.
  • A Debt to Equity ratio of 1.9% means that company has 0.02 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of DNA Biomed Solns:

  • The MRQ is 0.019. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.019. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.019TTM0.0190.000
TTM0.019YOY0.023-0.005
TTM0.0195Y0.335-0.317
5Y0.33510Y0.205+0.130
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0190.395-0.376
TTM0.0190.411-0.392
YOY0.0230.339-0.316
5Y0.3350.438-0.103
10Y0.2050.469-0.264

2. Market Valuation of DNA Biomed Solns

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings DNA Biomed Solns generates.

  • Above 15 is considered overpriced but always compare DNA Biomed Solns to the Biotechnology industry mean.
  • A PE ratio of -66.13 means the investor is paying -66.13 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of DNA Biomed Solns:

  • The EOD is -92.190. Based on the earnings, the company is expensive. -2
  • The MRQ is -66.134. Based on the earnings, the company is expensive. -2
  • The TTM is -66.134. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-92.190MRQ-66.134-26.056
MRQ-66.134TTM-66.1340.000
TTM-66.134YOY-3.841-62.293
TTM-66.1345Y-13.275-52.859
5Y-13.27510Y-13.666+0.391
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-92.190-2.437-89.753
MRQ-66.134-2.599-63.535
TTM-66.134-2.764-63.370
YOY-3.841-4.018+0.177
5Y-13.275-6.401-6.874
10Y-13.666-6.590-7.076
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of DNA Biomed Solns:

  • The EOD is -160.041. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -114.808. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -114.808. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-160.041MRQ-114.808-45.233
MRQ-114.808TTM-114.8080.000
TTM-114.808YOY-255.374+140.566
TTM-114.8085Y-133.218+18.410
5Y-133.21810Y-94.735-38.483
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-160.041-3.111-156.930
MRQ-114.808-3.321-111.487
TTM-114.808-3.598-111.210
YOY-255.374-5.480-249.894
5Y-133.218-8.353-124.865
10Y-94.735-8.955-85.780
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of DNA Biomed Solns is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.98 means the investor is paying 0.98 for each 1 in book value.

Let's take a look of the Price to Book Ratio trends of DNA Biomed Solns:

  • The EOD is 1.370. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.983. Based on the equity, the company is cheap. +2
  • The TTM is 0.983. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.370MRQ0.983+0.387
MRQ0.983TTM0.9830.000
TTM0.983YOY1.129-0.146
TTM0.9835Y4.051-3.068
5Y4.05110Y-2.593+6.644
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.3702.051-0.681
MRQ0.9832.143-1.160
TTM0.9832.120-1.137
YOY1.1292.878-1.749
5Y4.0513.601+0.450
10Y-2.5933.972-6.565
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of DNA Biomed Solns compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.746-0.7460%20.927-104%2.319-132%5.496-114%
Book Value Per Share--64.29464.2940%65.040-1%40.557+59%23.030+179%
Current Ratio--97.72697.7260%83.563+17%52.999+84%26.904+263%
Debt To Asset Ratio--0.0180.0180%0.023-21%0.170-89%0.708-97%
Debt To Equity Ratio--0.0190.0190%0.023-21%0.335-94%0.205-91%
Dividend Per Share----0%-0%-0%-0%
Eps---0.956-0.9560%-19.109+1900%-10.415+990%-2.177+128%
Free Cash Flow Per Share---0.550-0.5500%-0.287-48%-0.868+58%-1.034+88%
Free Cash Flow To Equity Per Share---0.550-0.5500%33.043-102%10.826-105%8.970-106%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.249--------
Intrinsic Value_10Y_min---7.369--------
Intrinsic Value_1Y_max---0.688--------
Intrinsic Value_1Y_min---0.876--------
Intrinsic Value_3Y_max---1.562--------
Intrinsic Value_3Y_min---2.528--------
Intrinsic Value_5Y_max---1.827--------
Intrinsic Value_5Y_min---4.054--------
Market Cap10850748400.000+28%7783971120.0007783971120.0000%9040244940.000-14%10806412092.000-28%17419085886.000-55%
Net Profit Margin---3.846-3.8460%-42.029+993%-9.175+139%-4.587+19%
Operating Margin----0%-10.1770%-2.0350%-1.0180%
Operating Ratio--8.1058.1050%11.177-27%3.856+110%1.928+320%
Pb Ratio1.370+28%0.9830.9830%1.129-13%4.051-76%-2.593+364%
Pe Ratio-92.190-39%-66.134-66.1340%-3.841-94%-13.275-80%-13.666-79%
Price Per Share88.100+28%63.20063.2000%73.400-14%87.740-28%141.430-55%
Price To Free Cash Flow Ratio-160.041-39%-114.808-114.8080%-255.374+122%-133.218+16%-94.735-17%
Price To Total Gains Ratio-118.071-39%-84.700-84.7000%3.507-2515%-16.773-80%2540.159-103%
Quick Ratio----0%-0%0.066-100%0.061-100%
Return On Assets---0.015-0.0150%-0.287+1867%-0.411+2718%-0.487+3240%
Return On Equity---0.015-0.0150%-0.294+1877%-0.752+4960%-0.185+1144%
Total Gains Per Share---0.746-0.7460%20.927-104%2.319-132%5.496-114%
Usd Book Value--21372571.30021372571.3000%21620609.400-1%13481990.820+59%7655740.490+179%
Usd Book Value Change Per Share---0.002-0.0020%0.056-104%0.006-132%0.015-114%
Usd Book Value Per Share--0.1740.1740%0.176-1%0.109+59%0.062+179%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.003-0.0030%-0.052+1900%-0.028+990%-0.006+128%
Usd Free Cash Flow---182992.200-182992.2000%-95544.600-48%-288631.060+58%-240561.870+31%
Usd Free Cash Flow Per Share---0.001-0.0010%-0.001-48%-0.002+58%-0.003+88%
Usd Free Cash Flow To Equity Per Share---0.001-0.0010%0.089-102%0.029-105%0.024-106%
Usd Market Cap29286169.932+28%21008938.05321008938.0530%24399621.093-14%29166506.236-28%47014112.806-55%
Usd Price Per Share0.238+28%0.1710.1710%0.198-14%0.237-28%0.382-55%
Usd Profit---317672.300-317672.3000%-6352366.400+1900%-3462169.240+990%-723628.890+128%
Usd Revenue--82589.40082589.4000%151144.000-45%46746.680+77%23373.340+253%
Usd Total Gains Per Share---0.002-0.0020%0.056-104%0.006-132%0.015-114%
 EOD+5 -3MRQTTM+0 -0YOY+13 -185Y+19 -1310Y+19 -13

3.2. Fundamental Score

Let's check the fundamental score of DNA Biomed Solns based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-92.190
Price to Book Ratio (EOD)Between0-11.370
Net Profit Margin (MRQ)Greater than0-3.846
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than197.726
Debt to Asset Ratio (MRQ)Less than10.018
Debt to Equity Ratio (MRQ)Less than10.019
Return on Equity (MRQ)Greater than0.15-0.015
Return on Assets (MRQ)Greater than0.05-0.015
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of DNA Biomed Solns based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.044
Ma 20Greater thanMa 5086.920
Ma 50Greater thanMa 10081.668
Ma 100Greater thanMa 20075.125
OpenGreater thanClose90.900
Total5/5 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in ILS. All numbers in thousands.

Summary
Total Assets80,658
Total Liabilities1,471
Total Stockholder Equity79,187
 As reported
Total Liabilities 1,471
Total Stockholder Equity+ 79,187
Total Assets = 80,658

Assets

Total Assets80,658
Total Current Assets66,942
Long-term Assets13,716
Total Current Assets
Cash And Cash Equivalents 66,698
Total Current Assets  (as reported)66,942
Total Current Assets  (calculated)66,698
+/- 244
Long-term Assets
Long-term Assets  (as reported)13,716
Long-term Assets  (calculated)0
+/- 13,716

Liabilities & Shareholders' Equity

Total Current Liabilities685
Long-term Liabilities786
Total Stockholder Equity79,187
Total Current Liabilities
Accounts payable 75
Total Current Liabilities  (as reported)685
Total Current Liabilities  (calculated)75
+/- 610
Long-term Liabilities
Long-term Liabilities  (as reported)786
Long-term Liabilities  (calculated)0
+/- 786
Total Stockholder Equity
Total Stockholder Equity (as reported)79,187
Total Stockholder Equity (calculated)0
+/- 79,187
Other
Capital Stock79,187
Common Stock Shares Outstanding 123,164
Net Invested Capital 79,187
Net Working Capital 66,257



Balance Sheet

Currency in ILS. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312006-12-312005-12-31
> Total Assets 
6,477
3,419
5,072
122
9,655
16,823
21,200
20,684
19,320
27,749
38,174
78,094
80,715
36,735
18,494
54,618
81,988
80,658
80,65881,98854,61818,49436,73580,71578,09438,17427,74919,32020,68421,20016,8239,6551225,0723,4196,477
   > Total Current Assets 
0
0
0
0
0
0
0
6,642
2,842
11,440
21,928
1,605
515
3,197
80
23,914
65,931
66,942
66,94265,93123,914803,1975151,60521,92811,4402,8426,6420000000
       Cash And Cash Equivalents 
4,959
164
2,386
88
1,674
830
2,180
3,012
2,425
8,709
16,942
1,517
492
373
42
23,690
65,729
66,698
66,69865,72923,690423734921,51716,9428,7092,4253,0122,1808301,674882,3861644,959
       Short-term Investments 
0
0
0
0
0
1,043
2,862
3,334
0
0
4,132
0
0
2,801
0
0
0
0
00002,801004,132003,3342,8621,04300000
       Net Receivables 
587
2,552
1,242
34
246
759
1,108
182
260
465
438
2
2
2
2
0
0
0
00022224384652601821,108759246341,2422,552587
       Other Current Assets 
0
48
10
0
0
0
27
114
157
129
4,278
11
13
2,813
36
224
13
0
013224362,81313114,2781291571142700010480
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
16,246
76,489
80,200
33,538
18,414
30,704
16,057
13,716
13,71616,05730,70418,41433,53880,20076,48916,2460000000000
       Property Plant Equipment 
931
655
179
0
0
18
18
99
649
752
766
0
0
0
0
0
0
0
000000076675264999181800179655931
       Goodwill 
0
0
0
0
0
803
803
803
900
903
890
0
0
0
0
0
0
0
000000089090390080380380300000
       Long Term Investments 
0
0
0
0
0
0
0
5,638
6,524
6,221
6,279
76,489
80,200
0
0
0
0
0
0000080,20076,4896,2796,2216,5245,6380000000
       Intangible Assets 
0
0
82
0
0
8,305
8,305
8,305
9,305
8,433
8,311
0
0
0
0
0
0
0
00000008,3118,4339,3058,3058,3058,305008200
       Other Assets 
0
0
29
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000002900
> Total Liabilities 
3,221
5,412
8,071
6,701
9,076
6,372
9,675
9,194
27,677
36,097
121,587
8,987
15,812
8,551
10,543
287
1,882
1,471
1,4711,88228710,5438,55115,8128,987121,58736,09727,6779,1949,6756,3729,0766,7018,0715,4123,221
   > Total Current Liabilities 
3,143
5,302
1,714
6,701
9,076
2,344
2,318
2,860
3,615
4,560
40,879
8,987
15,812
8,551
10,543
287
789
685
68578928710,5438,55115,8128,98740,8794,5603,6152,8602,3182,3449,0766,7011,7145,3023,143
       Short-term Debt 
0
0
0
0
0
0
0
6,980
1,641
831
38,007
0
0
0
0
0
0
0
000000038,0078311,6416,9800000000
       Short Long Term Debt 
0
0
0
0
0
0
0
6,980
1,641
831
38,007
0
0
0
283
0
0
0
00028300038,0078311,6416,9800000000
       Accounts payable 
253
466
160
297
2,218
63
23
49
508
1,390
206
13
17
0
0
0
87
75
758700017132061,3905084923632,218297160466253
       Other Current Liabilities 
633
1,424
1,554
1,802
1,834
1,516
1,491
1,426
1,466
77
77
8,734
15,142
8,104
9,262
0
305
0
030509,2628,10415,1428,73477771,4661,4261,4911,5161,8341,8021,5541,424633
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
80,708
0
0
0
0
0
1,093
786
7861,0930000080,7080000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
43,464
0
0
0
0
0
1,093
0
01,0930000043,4640000000000
> Total Stockholder Equity
3,256
0
0
0
579
9,586
10,623
10,022
-67,039
-79,374
-83,251
69,107
64,903
28,184
7,951
54,331
80,106
79,187
79,18780,10654,3317,95128,18464,90369,107-83,251-79,374-67,03910,02210,6239,5865790003,256
   Common Stock
1
1
132
132
35,721
45,766
46,352
49,005
49,397
56,025
56,025
65,818
66,269
69,637
71,858
99,352
141,091
0
0141,09199,35271,85869,63766,26965,81856,02556,02549,39749,00546,35245,76635,72113213211
   Retained Earnings Total Equity000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
7,743
2,565
1,137
3,192
-1,599
8,033
6,480
3,291
3,803
11,375
0
011,3753,8033,2916,4808,033-1,5993,1921,1372,5657,7430000000



Balance Sheet

Currency in ILS. All numbers in thousands.




Cash Flow

Currency in ILS. All numbers in thousands.




Income Statement

Currency in ILS. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue306
Cost of Revenue--
Gross Profit-306
 
Operating Income (+$)
Gross Profit-
Operating Expense-2,480
Operating Income-2,174-2,480
 
Operating Expense (+$)
Research Development-
Selling General Administrative1,093
Selling And Marketing Expenses-
Operating Expense2,4801,093
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-2,233
Net Interest Income2,233
 
Pretax Income (+$)
Operating Income-2,174
Net Interest Income2,233
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-1,177-2,174
EBIT - interestExpense = 0
-1,177
-1,177
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--1,177
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-1,177
Tax Provision--
Net Income From Continuing Ops-1,177-1,177
Net Income-1,177
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--2,233
 

Technical Analysis of DNA Biomed Solns
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of DNA Biomed Solns. The general trend of DNA Biomed Solns is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine DNA Biomed Solns's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of DNA Biomed Solns.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 104.90 < 105.00 < 105.00.

The bearish price targets are: 75.10 > 72.50 > 68.00.

Tweet this
DNA Biomed Solns Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of DNA Biomed Solns. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

DNA Biomed Solns Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of DNA Biomed Solns. The current macd is 1.98509782.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the DNA Biomed Solns price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for DNA Biomed Solns. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the DNA Biomed Solns price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
DNA Biomed Solns Daily Moving Average Convergence/Divergence (MACD) ChartDNA Biomed Solns Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of DNA Biomed Solns. The current adx is 20.89.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy DNA Biomed Solns shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
DNA Biomed Solns Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of DNA Biomed Solns. The current sar is 100.67.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
DNA Biomed Solns Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of DNA Biomed Solns. The current rsi is 54.04. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
DNA Biomed Solns Daily Relative Strength Index (RSI) ChartDNA Biomed Solns Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of DNA Biomed Solns. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the DNA Biomed Solns price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
DNA Biomed Solns Daily Stochastic Oscillator ChartDNA Biomed Solns Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of DNA Biomed Solns. The current cci is 33.43.

DNA Biomed Solns Daily Commodity Channel Index (CCI) ChartDNA Biomed Solns Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of DNA Biomed Solns. The current cmo is 5.35840053.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
DNA Biomed Solns Daily Chande Momentum Oscillator (CMO) ChartDNA Biomed Solns Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of DNA Biomed Solns. The current willr is -64.75095785.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that DNA Biomed Solns is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
DNA Biomed Solns Daily Williams %R ChartDNA Biomed Solns Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of DNA Biomed Solns.

DNA Biomed Solns Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of DNA Biomed Solns. The current atr is 5.31382031.

DNA Biomed Solns Daily Average True Range (ATR) ChartDNA Biomed Solns Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of DNA Biomed Solns. The current obv is 4,855,765.

DNA Biomed Solns Daily On-Balance Volume (OBV) ChartDNA Biomed Solns Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of DNA Biomed Solns. The current mfi is 71.82.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
DNA Biomed Solns Daily Money Flow Index (MFI) ChartDNA Biomed Solns Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for DNA Biomed Solns.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-17STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-31STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-15MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-21MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-14ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-05-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-06STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

DNA Biomed Solns Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of DNA Biomed Solns based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.044
Ma 20Greater thanMa 5086.920
Ma 50Greater thanMa 10081.668
Ma 100Greater thanMa 20075.125
OpenGreater thanClose90.900
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of DNA Biomed Solns with someone you think should read this too:
  • Are you bullish or bearish on DNA Biomed Solns? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about DNA Biomed Solns? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about DNA Biomed Solns

I send you an email if I find something interesting about DNA Biomed Solns.


Comments

How you think about this?

Leave a comment

Stay informed about DNA Biomed Solns.

Receive notifications about DNA Biomed Solns in your mailbox!